尔康制药(300267.SZ)发预亏，预计2025年度归母净亏损3.25亿元至3.85亿元

Core Viewpoint - Erkang Pharmaceutical (300267.SZ) has disclosed its performance forecast for the year 2025, expecting a net loss attributable to shareholders of the listed company between 325 million and 385 million yuan, with a net loss of 332 million to 392 million yuan after deducting non-recurring gains and losses [1] Financial Performance - The company anticipates a net loss of 325 million to 385 million yuan for 2025 [1] - The expected net loss after excluding non-recurring items is projected to be between 332 million and 392 million yuan [1]